NCT04790773

Alexa, What is Eliquis and Xarelto?

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Cedars-Sinai Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.

Detailed description

Anticoagulants are considered high-risk medications due to the risk of major bleeding. The Federal Drug and Food Administration (FDA) MedWatch reporting system found that anticoagulants had the most adverse drug event (ADE) reports in 2011. Anticoagulants have also been reported as one of the leading drug classes contributing to emergency department visits3. Given the potential for serious adverse events, providing effective education to increase patient knowledge and awareness of those risks are essential. Incorporating technology into health care is becoming increasingly popular and has been shown to be effective for patient education. One reason is that technology can consistently provide complete patient education and is not subject to educator variability in providing this education.

Conditions

• Patient Engagement
• Patient Satisfaction

Interventions

Type	Name	Description
OTHER	Amazon Alexa based voice recording patient education	Amazon Alexa based voice recording of medication education material

Timeline

• Start date: 2021-05-21
• Primary completion: 2021-06-30
• Completion: 2021-10-31
• First posted: 2021-03-10
• Last updated: 2022-03-21

Locations

1 site across 1 country: United States